Benjamin J. Zeskind net worth and biography

Benjamin Zeskind Biography and Net Worth

CEO of Immuneering

Dr. Zeskind has served as our Co-Founder, President, Chief Executive Officer and a member of our board of directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.

What is Benjamin J. Zeskind's net worth?: The estimated net worth of Benjamin J. Zeskind is at least $13.54 million as of July 1st, 2025. Zeskind owns 2,305,837 shares of Immuneering stock worth more than $13,535,263 as of April 24th. This net worth approximation does not reflect any other investments that Zeskind may own. Learn More about Benjamin J. Zeskind's net worth.
How do I contact Benjamin J. Zeskind?: The corporate mailing address for Zeskind and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Benjamin J. Zeskind's contact information.
Has Benjamin J. Zeskind been buying or selling shares of Immuneering?: Benjamin J. Zeskind has not been actively trading shares of Immuneering over the course of the past ninety days. Most recently, on Wednesday, July 2nd, Benjamin J. Zeskind bought 7,015 shares of Immuneering stock. The stock was acquired at an average cost of $3.53 per share, with a total value of $24,762.95. Following the completion of the transaction, the chief executive officer now directly owns 2,312,852 shares of the company's stock, valued at $8,164,367.56. Learn More on Benjamin J. Zeskind's trading history.
Are insiders buying or selling shares of Immuneering?: In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.
Information on this page was last updated on 1/16/2026.

Benjamin J. Zeskind Insider Trading History at Immuneering

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2025	Buy	7,015	$3.53	$24,762.95	2,312,852
7/1/2025	Buy	2,985	$3.38	$10,089.30	2,305,837
6/18/2025	Buy	21,000	$2.39	$50,190.00	2,302,852
3/19/2024	Buy	20,000	$2.77	$55,400.00	2,281,852
3/23/2022	Buy	3,000	$8.02	$24,060.00

Benjamin J. Zeskind Buying and Selling Activity at Immuneering

Immuneering Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Today's Range

Now: $6.00

$5.82

$6.22

50 Day Range

MA: $5.27

$4.78

$6.13

2 Week Range

Now: $6.00

$1.10

$10.08

Volume

300,810 shs

Average Volume

1,447,339 shs

Market Capitalization

$387.88 million

P/E Ratio

N/A

Dividend Yield